DecisionDx-SCC is a 40-gene expression profile test that uses an individual patient’s tumor biology to stratify risk of metastasis in patients with cutaneous squamous cell carcinoma who have one or more National Comprehensive Cancer Network (NCCN) high-risk factors. More: https://bit.ly/3XM95Q4
Castle Biosciences, Inc.
Biotechnology Research
Friendswood, Texas 12,579 followers
Improving health through innovative tests that guide patient care
About us
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
- Website
-
http://www.castlebiosciences.com
External link for Castle Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Friendswood, Texas
- Type
- Public Company
- Founded
- 2008
- Specialties
- Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma, Gene Expression Profile Tests, Barrett's Esophagus, Esophageal Adenocarcinoma, and Dermatologic Cancer
Locations
-
Primary
505 S Friendswood Dr
Suite 401
Friendswood, Texas 77546, US
-
3737 N 7th St
Suite 160
Phoenix, Arizona 85014, US
-
235 William Pitt Way
B1
Pittsburgh, Pennsylvania 15238, US
Employees at Castle Biosciences, Inc.
Updates
-
October is National Depression & Mental Heath Screening month, whose goal is to increase awareness about depression, mental health more broadly, and the importance of mental health screening. #IDgenetix #PGxtesting #MentalHealthAwareness #FallIntoHealthyHabits
-
This week's #CasesWithCastle features #TissueCypher...
“The straightforward decision to ablate or not ablate is not that straightforward. [TissueCypher] helped us to reassure a patient who is very anxious about this diagnosis of #BarrettsEsophagus.” In this week's #CasesWithCastle, Dr. Jay Yepuri, MD, MS, FACG from Digestive Health Associates of Texas works with a 52-year-old male patient with a history of alcoholic cirrhosis complicated by portal hypertensive changes. The patient was referred by a colleague for consideration of EET. See the full case details: https://lnkd.in/dQnNZc3s #TissueCypher
-
On this #RareCancerDay, we'd like to recognize one that's close to our heart❤️: uveal (ocular) melanoma. While #UvealMelanoma👀 is indeed rare, affecting 5 or 6 out of 1 million people each year, it is actually the most common primary intraocular tumor in adults and is also the 2nd most common type of primary malignant melanoma—representing ~5%-6% of all melanoma diagnoses (second only to cutaneous melanoma). #DecisionDxUM is the standard of care for evaluating metastatic risk in uveal melanoma. https://hubs.la/Q02Rxvw70
-
Castle’s phenomenal CFO, Frank Stokes, was an honored guest at the Texas Governor’s Mansion today in Austin, Texas. Governor Greg Abbott hosted Texas Stock Exchange (TXSE) board of directors, executive team, investors and other notable business leaders to discuss the role of the TXSE in boosting economic growth and establishing Texas as the new engine of the nation’s capital markets.
-
Castle presents NEW DATA at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting. In the study, patients with lower-stage Brigham and Women's Hospital (BWH) T1-T2a cutaneous squamous cell carcinoma (SCC) tumors were further stratified into distinct groups of those with more or less favorable survival by the DecisionDx-SCC test, including in the T2a immunosuppressed patient subset which showed a higher rate of metastasis. Highlights/details: https://hubs.la/Q02Rvt-X0 #DecisionDxSCC
-
Castle Biosciences, Inc. reposted this
Are you attending #ASTRO24? Make sure to stop by our booth! Castle Biosciences, Inc. American Society for Radiation Oncology (ASTRO)
-
#FallIntoHealthyHabits: Ocular Edition When it comes to staying healthy, we can't forget our 👀 EYES! Many eye diseases, such as uveal melanoma (the most common form of eye cancer), can have no symptoms, so regular exams, including dilated eye exams, are critical to early diagnosis. #LoveYourEyes #UvealMelanoma #OcularMelanoma #DecisionDxUM #CastleCares
-
#TeamCastle invites you to check out our product theater this Saturday during the JADPRO Insight Forum! See you there! DecisionDx-Melanoma DecisionDx-SCC MyPath Melanoma
-
This week: Castle will present NEW DATA supporting its TissueCypher Barrett's Esophagus test (TSP-9) at the American Foregut Society (AFS) 2024 Annual Meeting 9/25-29 in Denver. Oral abstract will share data showing that TissueCypher alone, compared to combining the test’s results with a patient’s clinicopathologic risk factors, like age and pathology diagnosis, is the strongest predictor of progression to esophageal cancer. Poster will highlight ability of the test to guide important patient management decisions, including upstaging care for high-risk patients and supporting long-interval surveillance for patients at low risk of progression. Highlights/details: https://hubs.la/Q02QN_sS0